Crista Ochsenfarth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Crista Ochsenfarth has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Ulrich Hermann Frey
Department of Anaesthesiology, Intensive Care, Pain and Palliative Medicine, Marien Hospital Herne, Ruhr University Bochum, Hölkeskampring 40, Herne, 44625, Germany.
4 shared publications Andrea Engler
Affiliation Department of Anaesthesiology and Intensive Care Medicine, Essen University Hospital and University of Duisburg-Essen, Essen, Germany
3 shared publicationsJürgen Peters
Affiliation Department of Anaesthesiology and Intensive Care Medicine, Essen University Hospital and University of Duisburg-Essen, Essen, Germany
3 shared publications- Adrien Noa-Bolaño
Institute of Molecular Oncology and Experimental Therapeutics, Division of Hematology and Oncology, Ruhr University Bochum Medical School, Marien Hospital Herne, 44625 Herne, Germany
2 shared publications - Ali Haydar Acikelli
Department of Haematology and Oncology, Institute of Molecular Oncology and Experimental Therapeutics, Marien Hospital Herne, University Clinic of Ruhr-University Bochum, 44265 Herne, Germany
2 shared publications - Bernd Giebel
Institute of Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
2 shared publications
Latest Publications
- Open Access
Neuro-Immune Crypt-Associated Cells and REST-Mediated Reprogramming: Pathogen-Driven Stromal Activation, HERVs Induction, and Abortive Antiviral Signaling in Colorectal Carcinoma
Colorectal cancer (CRC) pathogenesis remains linked to poorly defined cellular origins and microenvironmental drivers. We identify Neuro-Immune Crypt-Associated (NICA) cells as a privileged pathogen portal and a plausible epithelial cell of origin. During carcinogenesis, the repressor REST drives a neuroendocrine-to-epithelial transition by silencing NICA-associated neuroendocrine markers, a lineage loss reversible via epigenetic modulation or genetic ablation in CRC models. This landscape is further shaped by EBV-infected B-lineage cells (BLEICS), which transactivate HERV-H/F elements in CRC cells through paracrine signaling, establishing a niche-restricted ‘viral scar’. While tumor crypts sense this retroviral pressure, they exhibit an abortive antiviral signature marked by RNase L downregulation, creating a functional execution gap. We propose a pathogen-first model where chronic inflammatory pressure triggers ‘mutation-silencing’ -the simultaneous genotoxic and epigenetic inactivation of tumor suppressors. Together, the convergence of NICA plasticity, BLEICS-mediated HERV induction, and compromised antiviral surveillance redefines CRC as a pathogen-driven disruption of the neuro-immune niche.
Open AccessNeuro-Immune Crypt-Associated Cells and REST-Mediated Reprogramming: Pathogen-Driven Stromal Activation, HERVs Induction, and Abortive Antiviral Signaling in Colorectal Carcinoma
Colorectal cancer (CRC) pathogenesis remains linked to poorly defined cellular origins and microenvironmental drivers. We identify Neuro-Immune Crypt-Associated (NICA) cells as a privileged pathogen portal and a plausible epithelial cell of origin. During carcinogenesis, the repressor REST drives a neuroendocrine-to-epithelial transition by silencing NICA-associated neuroendocrine markers, a lineage loss reversible via epigenetic modulation or genetic ablation in CRC models. This landscape is further shaped by EBV-infected B-lineage cells (BLEICS), which transactivate HERV-H/F elements in CRC cells through paracrine signaling, establishing a niche-restricted ‘viral scar’. While tumor crypts sense this retroviral pressure, they exhibit an abortive antiviral signature marked by RNase L downregulation, creating a functional execution gap. We propose a pathogen-first model where chronic inflammatory pressure triggers ‘mutation-silencing’ -the simultaneous genotoxic and epigenetic inactivation of tumor suppressors. Together, the convergence of NICA plasticity, BLEICS-mediated HERV induction, and compromised antiviral surveillance redefines CRC as a pathogen-driven disruption of the neuro-immune niche.
- Open Access
- 28 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9304
Influence of Anesthetic Regimes on Extracellular Vesicles following Remote Ischemic Preconditioning in Coronary Artery Disease
Remote ischemic preconditioning (RIPC) reduces ischemia-reperfusion injury in aortocoronary bypass surgery, potentially via extracellular vesicles (EVs) and their micro-RNA content. Clinical data implicate that propofol might inhibit the cardioprotective RIPC effect. This prospective, randomized study investigated the influence of different anesthetic regimes on RIPC efficacy and EV micro-RNA signatures. We also assessed the impact of propofol on cell protection after hypoxic conditioning and EV-mediated RIPC in vitro. H9c2 rat cardiomyoblasts were subjected to hypoxia, with or without propofol, and subsequent simulated ischemia-reperfusion injury. Apoptosis was measured by flow cytometry. Blood samples of 64 patients receiving anesthetic maintenance with propofol or isoflurane, along with RIPC or sham procedures, were analyzed, and EVs were enriched using a polymer-based method. Propofol administration corresponded with increased Troponin T levels (4669 ± 435.6 pg/mL), suggesting an inhibition of the cardioprotective RIPC effect. RIPC leads to a notable rise in miR-21 concentrations in the group receiving propofol anesthesia (fold change 7.22 ± 6.6). In vitro experiments showed that apoptosis reduction was compromised with propofol and only occurred in an EV-enriched preconditioning medium, not in an EV-depleted medium. Our study could clinically and experimentally confirm propofol inhibition of RIPC protection. Increased miR-21 expression could provide evidence for a possible inhibitory mechanism.
- 28 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9304
Open AccessInfluence of Anesthetic Regimes on Extracellular Vesicles following Remote Ischemic Preconditioning in Coronary Artery Disease
Remote ischemic preconditioning (RIPC) reduces ischemia-reperfusion injury in aortocoronary bypass surgery, potentially via extracellular vesicles (EVs) and their micro-RNA content. Clinical data implicate that propofol might inhibit the cardioprotective RIPC effect. This prospective, randomized study investigated the influence of different anesthetic regimes on RIPC efficacy and EV micro-RNA signatures. We also assessed the impact of propofol on cell protection after hypoxic conditioning and EV-mediated RIPC in vitro. H9c2 rat cardiomyoblasts were subjected to hypoxia, with or without propofol, and subsequent simulated ischemia-reperfusion injury. Apoptosis was measured by flow cytometry. Blood samples of 64 patients receiving anesthetic maintenance with propofol or isoflurane, along with RIPC or sham procedures, were analyzed, and EVs were enriched using a polymer-based method. Propofol administration corresponded with increased Troponin T levels (4669 ± 435.6 pg/mL), suggesting an inhibition of the cardioprotective RIPC effect. RIPC leads to a notable rise in miR-21 concentrations in the group receiving propofol anesthesia (fold change 7.22 ± 6.6). In vitro experiments showed that apoptosis reduction was compromised with propofol and only occurred in an EV-enriched preconditioning medium, not in an EV-depleted medium. Our study could clinically and experimentally confirm propofol inhibition of RIPC protection. Increased miR-21 expression could provide evidence for a possible inhibitory mechanism.
- Open Access
- 3 March 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-16
Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors
In this work, we are reporting that “Shock and Kill”, a therapeutic approach designed to eliminate latent HIV from cell reservoirs, is extrapolatable to cancer therapy. This is based on the observation that malignant cells express a spectrum of human endogenous retroviral elements (HERVs) which can be transcriptionally boosted by HDAC inhibitors. The endoretroviral geneHERV-V2codes for an envelope protein, which resembles syncytins. It is significantly overexpressed upon exposure to HDAC inhibitors and can be effectively targeted by simultaneous application of TLR7/8 agonists, triggering intrinsic apoptosis. We demonstrated that this synergistic cytotoxic effect was accompanied by the functional disruption of the TLR7/8-NFκB, Akt/PKB, and Ras-MEK-ERK signalling pathways. CRISPR/Cas9 ablation ofTLR7andHERV-V1/V2curtailed apoptosis significantly, proving the pivotal role of these elements in driving cell death. The effectiveness of this new approach was confirmed in ovarian tumour xenograft studies, revealing a promising avenue for future cancer therapies.
- 3 March 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-16
Open AccessEnhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors
In this work, we are reporting that “Shock and Kill”, a therapeutic approach designed to eliminate latent HIV from cell reservoirs, is extrapolatable to cancer therapy. This is based on the observation that malignant cells express a spectrum of human endogenous retroviral elements (HERVs) which can be transcriptionally boosted by HDAC inhibitors. The endoretroviral geneHERV-V2codes for an envelope protein, which resembles syncytins. It is significantly overexpressed upon exposure to HDAC inhibitors and can be effectively targeted by simultaneous application of TLR7/8 agonists, triggering intrinsic apoptosis. We demonstrated that this synergistic cytotoxic effect was accompanied by the functional disruption of the TLR7/8-NFκB, Akt/PKB, and Ras-MEK-ERK signalling pathways. CRISPR/Cas9 ablation ofTLR7andHERV-V1/V2curtailed apoptosis significantly, proving the pivotal role of these elements in driving cell death. The effectiveness of this new approach was confirmed in ovarian tumour xenograft studies, revealing a promising avenue for future cancer therapies.
- Open Access
- 18 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0247087
Characterization of the G protein-coupled receptor kinase 6 promoter reveals a functional CREB binding site
Background: G protein-coupled receptor kinase 6 (GRK6) is part of the G protein-coupled receptor kinase family, whose members act as key regulators of seven-transmembrane receptor signalling. GRK6 seems to play a role in regulation of inflammatory processes, but mechanisms of transcriptional regulation of GRK6 expression in inflammatory cell lines have not been characterized. Protein kinase C (PKC) signalling is also involved in inflammatory regulation and an impact of PKC activation on GRK6 protein expression was described previously. Thus, the aim of this study was to 1) characterize theGRK6promoter, and 2) investigate a potential influence of PKC on GRK6 expression.Methods: Five deletion constructs of theGRK6promoter were cloned. After transient transfection into a human T cell line, promoter activity was assessed using luciferase reporter gene assays. Putative transcription factor binding sites were identified, mutated, and binding was investigated using electrophoretic mobility shift assays (EMSA). Following stimulation with a PKC activator, GRK6 expression on mRNA and protein levels was assessed by reverse transcriptase qPCR and Western blots.Results: Investigation of theGRK6promoter revealed a putative cAMP responsive element (CRE), whose mutation led to decreased promoter activity (p = 0.0006). Functionality of the CRE binding protein (CREB) binding site was verified in EMSA blots. Stimulation with a PKC activator resulted in decreasedGRK6promoter activity (p = 0.0027), mRNA (p = 0.04) and protein expression.Conclusion: We characterized the humanGRK6promoter and identified promoter activity to be influenced by a CREB binding site. PKC might be one determinant contributing to altered GRK6 expression.
- 18 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0247087
Open AccessCharacterization of the G protein-coupled receptor kinase 6 promoter reveals a functional CREB binding site
Background: G protein-coupled receptor kinase 6 (GRK6) is part of the G protein-coupled receptor kinase family, whose members act as key regulators of seven-transmembrane receptor signalling. GRK6 seems to play a role in regulation of inflammatory processes, but mechanisms of transcriptional regulation of GRK6 expression in inflammatory cell lines have not been characterized. Protein kinase C (PKC) signalling is also involved in inflammatory regulation and an impact of PKC activation on GRK6 protein expression was described previously. Thus, the aim of this study was to 1) characterize theGRK6promoter, and 2) investigate a potential influence of PKC on GRK6 expression.Methods: Five deletion constructs of theGRK6promoter were cloned. After transient transfection into a human T cell line, promoter activity was assessed using luciferase reporter gene assays. Putative transcription factor binding sites were identified, mutated, and binding was investigated using electrophoretic mobility shift assays (EMSA). Following stimulation with a PKC activator, GRK6 expression on mRNA and protein levels was assessed by reverse transcriptase qPCR and Western blots.Results: Investigation of theGRK6promoter revealed a putative cAMP responsive element (CRE), whose mutation led to decreased promoter activity (p = 0.0006). Functionality of the CRE binding protein (CREB) binding site was verified in EMSA blots. Stimulation with a PKC activator resulted in decreasedGRK6promoter activity (p = 0.0027), mRNA (p = 0.04) and protein expression.Conclusion: We characterized the humanGRK6promoter and identified promoter activity to be influenced by a CREB binding site. PKC might be one determinant contributing to altered GRK6 expression.
- 11 December 2018
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 63 (4) , 483-492
Remote ischaemic preconditioning increases serum extracellular vesicle concentrations with altered micro‐RNA signature in CABG patients
Background: Remote ischaemic preconditioning (RIPC) can attenuate myocardial ischaemia/reperfusion injury but its underlying mechanisms remain largely unknown. Recently, extracellular vesicles (EVs) containing microRNAs (miRNAs) were shown to mediate distant intercellular communication that may be involved in cardioprotection. We tested the hypothesis that RIPC in anaesthetized patients undergoing coronary artery bypass (CABG) surgery results in the release of EVs from the ischaemic/reperfused arm into the blood stream harbouring cardioprotective miRNAs.Methods: In 58 patients randomised to RIPC (three 5/5 minutes episodes of left arm ischaemia/reperfusion by suprasystolic blood pressure cuff inflations/deflations) or Sham, a subprotocol comprising of parallel right radial artery and regional (left subclavian) venous blood sampling before (awake) and 5 and 60 minutes after RIPC/Sham during isoflurane/sufentanil anaesthesia could be completed. EVs were extracted by polymer‐based precipitation methods, their concentrations measured, and their miRNA signature analysed.Results: Five minutes after RIPC, regional venous EV concentrations downstream from the cuff increased and arterial concentrations increased after 60 minutes (fold change [fc]: RIPC: 1.33 ± 0.5, Sham: 0.91 ± 0.31; P = 0.003 for interaction). Already 5 minutes after RIPC, expression of 26 miRNAs (threshold fc: 3.0, P < 0.05) isolated from EVs including the cardioprotective miR‐21 had increased. RIPC also decreased postoperative Troponin I concentrations (AUC RIPC: 336 ng/mL × 72 hours ± 306 vs Sham: 713 ± 1013; P = 0.041).Conclusions: Remote ischaemic preconditioning increases serum EV concentrations, most likely by early EV release from the patients’ left (RIPC) arm, alters their miRNA signature, and is associated with myocardial protection. Thus, an increased EV concentration with an altered miR‐signature may mediate the RIPC effect.
- 11 December 2018
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 63 (4) , 483-492
Remote ischaemic preconditioning increases serum extracellular vesicle concentrations with altered micro‐RNA signature in CABG patients
Background: Remote ischaemic preconditioning (RIPC) can attenuate myocardial ischaemia/reperfusion injury but its underlying mechanisms remain largely unknown. Recently, extracellular vesicles (EVs) containing microRNAs (miRNAs) were shown to mediate distant intercellular communication that may be involved in cardioprotection. We tested the hypothesis that RIPC in anaesthetized patients undergoing coronary artery bypass (CABG) surgery results in the release of EVs from the ischaemic/reperfused arm into the blood stream harbouring cardioprotective miRNAs.Methods: In 58 patients randomised to RIPC (three 5/5 minutes episodes of left arm ischaemia/reperfusion by suprasystolic blood pressure cuff inflations/deflations) or Sham, a subprotocol comprising of parallel right radial artery and regional (left subclavian) venous blood sampling before (awake) and 5 and 60 minutes after RIPC/Sham during isoflurane/sufentanil anaesthesia could be completed. EVs were extracted by polymer‐based precipitation methods, their concentrations measured, and their miRNA signature analysed.Results: Five minutes after RIPC, regional venous EV concentrations downstream from the cuff increased and arterial concentrations increased after 60 minutes (fold change [fc]: RIPC: 1.33 ± 0.5, Sham: 0.91 ± 0.31; P = 0.003 for interaction). Already 5 minutes after RIPC, expression of 26 miRNAs (threshold fc: 3.0, P < 0.05) isolated from EVs including the cardioprotective miR‐21 had increased. RIPC also decreased postoperative Troponin I concentrations (AUC RIPC: 336 ng/mL × 72 hours ± 306 vs Sham: 713 ± 1013; P = 0.041).Conclusions: Remote ischaemic preconditioning increases serum EV concentrations, most likely by early EV release from the patients’ left (RIPC) arm, alters their miRNA signature, and is associated with myocardial protection. Thus, an increased EV concentration with an altered miR‐signature may mediate the RIPC effect.
- 15 June 2018
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 123 (6) , 660-669
TheGRK2Promoter Is Regulated by Early‐Growth Response Transcription FactorEGR‐1
The G‐protein‐coupled receptor kinase 2 (GRK2) plays a major role in cardiovascular diseases, and its expression is increased in heart failure. However, only little is known about factors being involved in up‐regulation ofGRK2 expression through transcriptional regulation of its promoter. Since the transcription factor early‐growth response 1 (EGR‐1) is also up‐regulated in patients with heart failure, we tested the hypothesis thatEGR‐1 regulatesGRK2transcription. Stimulation of immortalized rat cardiomyocytes (H9c2) with phorbol 12‐myristate 13‐acetate (PMA) resulted in up‐regulation ofEgr‐1and subsequently ofGrk2mRNAexpression, with maximumGrk2expression (p= 0.008) 5 hr afterPMAstimulation and being abolished by actinomycin D, indicating a transcriptional mechanism. To identify naturally occurring variants affecting promoter transcriptional activity, we identified a novel G(‐43)A polymorphism (rs182084609), which surrounded a putativeEGR‐1‐binding site. While the minor A allele frequency was rare (0.02), this variant was used to explore regulation byEGR‐1 and promoter construct with altered alleles at nt‐43 were subjected of reporter assays in human embryonic kidney cells (Hek293). Here,EGR‐1 over‐expression resulted in a more than twofold increase inGRK2promoter activity but only in the presence of the G‐allele (p= 0.04). In electrophoretic mobility shift assays,EGR‐1 over‐expression resulted in a specific binding of transcription factors only to the G oligonucleotide. Finally,EGR‐1 over‐expression resulted in increasedGRK2mRNAexpression (p= 0.03). We identifiedEGR‐1 as a regulator ofGRK2transcription. Suppression ofGRK2 expression by inhibition ofEGR‐1 binding toGRK2might be a promising approach to mitigate adrenergic desensitization.
- 15 June 2018
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 123 (6) , 660-669
TheGRK2Promoter Is Regulated by Early‐Growth Response Transcription FactorEGR‐1
The G‐protein‐coupled receptor kinase 2 (GRK2) plays a major role in cardiovascular diseases, and its expression is increased in heart failure. However, only little is known about factors being involved in up‐regulation ofGRK2 expression through transcriptional regulation of its promoter. Since the transcription factor early‐growth response 1 (EGR‐1) is also up‐regulated in patients with heart failure, we tested the hypothesis thatEGR‐1 regulatesGRK2transcription. Stimulation of immortalized rat cardiomyocytes (H9c2) with phorbol 12‐myristate 13‐acetate (PMA) resulted in up‐regulation ofEgr‐1and subsequently ofGrk2mRNAexpression, with maximumGrk2expression (p= 0.008) 5 hr afterPMAstimulation and being abolished by actinomycin D, indicating a transcriptional mechanism. To identify naturally occurring variants affecting promoter transcriptional activity, we identified a novel G(‐43)A polymorphism (rs182084609), which surrounded a putativeEGR‐1‐binding site. While the minor A allele frequency was rare (0.02), this variant was used to explore regulation byEGR‐1 and promoter construct with altered alleles at nt‐43 were subjected of reporter assays in human embryonic kidney cells (Hek293). Here,EGR‐1 over‐expression resulted in a more than twofold increase inGRK2promoter activity but only in the presence of the G‐allele (p= 0.04). In electrophoretic mobility shift assays,EGR‐1 over‐expression resulted in a specific binding of transcription factors only to the G oligonucleotide. Finally,EGR‐1 over‐expression resulted in increasedGRK2mRNAexpression (p= 0.03). We identifiedEGR‐1 as a regulator ofGRK2transcription. Suppression ofGRK2 expression by inhibition ofEGR‐1 binding toGRK2might be a promising approach to mitigate adrenergic desensitization.
- 26 April 2012
- Published by Springer Nature
- Vol. 882, 123-142
Simple Methods for the Detection of HLA-G Variants in Coding and Non-coding Regions
The non-classical human leukocyte antigen (HLA)-G plays a crucial role in the induction of tolerance at the feto–maternal interface as well as in transplantation, cancer, inflammation, and autoimmune diseases. To understand gene regulation and the impact of polymorphic sites on the function, simple and easy feasible approaches are needed for the detection of HLA-G variants in coding and non-coding regions. Here we summarize a set of methods for the identification of variants in the exon 2–4, in the 3′ untranslated region and in the gene promoter region of the HLA-G gene.
- 26 April 2012
- Published by Springer Nature
- Vol. 882, 123-142
Simple Methods for the Detection of HLA-G Variants in Coding and Non-coding Regions
The non-classical human leukocyte antigen (HLA)-G plays a crucial role in the induction of tolerance at the feto–maternal interface as well as in transplantation, cancer, inflammation, and autoimmune diseases. To understand gene regulation and the impact of polymorphic sites on the function, simple and easy feasible approaches are needed for the detection of HLA-G variants in coding and non-coding regions. Here we summarize a set of methods for the identification of variants in the exon 2–4, in the 3′ untranslated region and in the gene promoter region of the HLA-G gene.